• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Altria Group Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    1/30/25 7:23:23 AM ET
    $MO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MO alert in real time by email
    mo-20250130
    false000076418000007641802025-01-302025-01-300000764180mo:CommonStock0.3313ParValueMember2025-01-302025-01-300000764180mo:CommonStock1.700NotesDue2025Member2025-01-302025-01-300000764180mo:CommonStock2.200NotesDue2027Member2025-01-302025-01-300000764180mo:CommonStock3.125NotesDue2031Member2025-01-302025-01-30

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     ____________________________________________________________________________________________________________
    FORM 8-K
    ________________________________________________________________________________________________________________
     CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): January 30, 2025
    ________________________________________________________________________________________________________________
    ALTRIA GROUP, INC.
    (Exact name of registrant as specified in its charter)
    ______________________________________________________________________________________________________________
    Virginia  1-08940  13-3260245
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)  (I.R.S. Employer
    Identification No.)
    6601 West Broad Street,Richmond,Virginia23230
    (Address of principal executive offices)        (Zip Code)
    Registrant’s telephone number, including area code: (804) 274-2200
    _______________________________________________________________________________________________________________
    (Former name or former address, if changed since last report.)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
                   Title of each class               
    Trading SymbolsName of each exchange on which registered
    Common Stock, $0.33 1/3 par value
    MONew York Stock Exchange
    1.700% Notes due 2025
    MO25New York Stock Exchange
    2.200% Notes due 2027
    MO27New York Stock Exchange
    3.125% Notes due 2031
    MO31New York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company
    ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 8.01.    Other Events.
    Filed as part of this Current Report on Form 8-K are the consolidated balance sheets of Altria Group, Inc. (“Altria”) and subsidiaries as of December 31, 2024 and 2023, and the related consolidated statements of earnings, comprehensive earnings, stockholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2024 (the “Financial Statements”); the independent registered public accounting firm’s report on the Financial Statements and the effectiveness of internal control over financial reporting; and the report of management on internal control over financial reporting. The Financial Statements, the independent registered public accounting firm’s report on the Financial Statements and the effectiveness of internal control over financial reporting and the report of management on internal control over financial reporting will also be filed as part of Altria’s Annual Report on Form 10-K for the year ended December 31, 2024.
    Item 9.01.    Financial Statements and Exhibits.
    (d)Exhibits
    23
    Consent of independent registered public accounting firm
    99.1
    Financial Statements
    99.2
    Report of independent registered public accounting firm
    99.3
    Report of management on internal control over financial reporting
    104The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101)


    2



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ALTRIA GROUP, INC.
    By:/s/ SALVATORE MANCUSO
    Name:Salvatore Mancuso
    Title:Executive Vice President and
    Chief Financial Officer
                            

    DATE:    January 30, 2025

    3
    Get the next $MO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MO

    DatePrice TargetRatingAnalyst
    4/1/2025Buy → Hold
    Deutsche Bank
    1/16/2025$54.00Equal-Weight
    Morgan Stanley
    12/6/2024$55.00 → $65.00Neutral → Buy
    BofA Securities
    10/8/2024$44.50 → $48.00Neutral
    Citigroup
    1/23/2024Sell
    UBS
    4/14/2023$52.00Buy
    Stifel
    11/10/2022$38.00Neutral → Sell
    UBS
    6/29/2022$53.00 → $36.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $MO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Gifford William F. Jr. was granted 31,037 shares and covered exercise/tax liability with 37,243 shares, decreasing direct ownership by 0.89% to 689,127 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      4/18/25 2:45:32 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Executive Officer Gifford William F. Jr. was granted 48,911 shares and covered exercise/tax liability with 55,488 shares, decreasing direct ownership by 0.94% to 695,333 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      3/3/25 3:08:57 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SVP, Chief HR Off. & CCO Whitaker Charles N. was granted 8,568 shares and covered exercise/tax liability with 7,511 shares, increasing direct ownership by 0.57% to 187,627 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      3/3/25 3:08:49 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Financials

    Live finance-specific insights

    See more
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Declares Regular Quarterly Dividend of $1.02 Per Share

      Altria Group, Inc. (NYSE:MO) today announced that our Board of Directors declared a regular quarterly dividend of $1.02 per share, payable on April 30, 2025 to shareholders of record as of March 25, 2025. The ex-dividend date is March 25, 2025. View source version on businesswire.com: https://www.businesswire.com/news/home/20250227441410/en/ Altria Client Services Investor Relations 804-484-8222 Altria Client Services Media Relations 804-484-8897 www.altria.com/contact-us/media

      2/27/25 3:00:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2024 Fourth-Quarter and Full-Year Results; Provides 2025 Full-Year Earnings Guidance; Announces New $1 Billion Share Repurchase Program

      Altria Group, Inc. (NYSE:MO) today reports our 2024 fourth-quarter and full-year business results and provides our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "2024 was another pivotal year for Altria, headlined by meaningful progress toward our Vision, strong financial results and significant cash returns to shareholders," said Billy Gifford, Altria's Chief Executive Officer. "Our companies' leading brands and talented teams enabled our core tobacco businesses to deliver solid income growth and margin expansion, while we strategically invested in our future." "We expect to deliver 2025 full-year adjusted diluted EPS in a range of $5.22 to $5.37. This range re

      1/30/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $MO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Altria to Host Webcast of 2025 Annual Meeting of Shareholders

      Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast of its 2025 Annual Meeting of Shareholders ("2025 Annual Meeting" or "meeting") on Thursday, May 15, 2025 at 9:00 a.m. Eastern Time. The 2025 Annual Meeting will be held virtually via live webcast. During the meeting, shareholders as of the 2025 Annual Meeting record date (March 25, 2025) will be able to vote their shares electronically and will be able to submit questions during the meeting as time permits. Although shareholders will be able to vote their shares during the meeting, they are encouraged to do so before the meeting using one of the methods described in the 2025 Proxy Statement. If you are not a shareholder

      5/1/25 10:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Reports 2025 First-Quarter Results; Reaffirms Full-Year Guidance

      Altria Group, Inc. (NYSE:MO) today reports our 2025 first-quarter business results and reaffirms our guidance for 2025 full-year adjusted diluted earnings per share (EPS). "Our highly profitable traditional tobacco businesses performed well in a challenging environment in the first quarter," said Billy Gifford, Altria's Chief Executive Officer. "The smokeable products segment delivered solid adjusted operating companies income growth behind the strength of Marlboro. In the oral tobacco products segment, on! maintained momentum in a competitive marketplace as Helix invested strategically behind the brand. And shareholders continued to benefit from strong cash returns through dividends and s

      4/29/25 7:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria to Host Webcast of 2025 First-Quarter Results

      Altria Group, Inc. (Altria) (NYSE:MO) will host a live audio webcast on Tuesday, April 29, 2025, at 9:00 a.m. Eastern Time to discuss its 2025 first-quarter business results. Altria will issue a press release containing its business results at approximately 7:00 a.m. Eastern Time the same day. The webcast can be accessed at altria.com. During the webcast, Billy Gifford, Altria's Chief Executive Officer, and Sal Mancuso, Altria's Chief Financial Officer, will discuss the Company's 2025 first-quarter business results and answer questions from the investment community and news media. The webcast will be in a listen-only mode. Pre-event registration is necessary; directions are posted at www.

      4/15/25 10:00:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Davis Robert Matthews bought $48,599 worth of shares (1,200 units at $40.50), increasing direct ownership by 16% to 8,473 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:08:44 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Clarke Ian L.T. bought $44,625 worth of shares (1,100 units at $40.57), increasing direct ownership by 18% to 7,145 units (SEC Form 4)

      4 - ALTRIA GROUP, INC. (0000764180) (Issuer)

      11/8/23 3:03:21 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria downgraded by Deutsche Bank

      Deutsche Bank downgraded Altria from Buy to Hold

      4/1/25 3:04:54 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Morgan Stanley initiated coverage on Altria with a new price target

      Morgan Stanley initiated coverage of Altria with a rating of Equal-Weight and set a new price target of $54.00

      1/16/25 7:47:52 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria upgraded by BofA Securities with a new price target

      BofA Securities upgraded Altria from Neutral to Buy and set a new price target of $65.00 from $55.00 previously

      12/6/24 7:56:47 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/13/24 4:58:48 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/13/23 2:49:28 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Altria Group Inc. (Amendment)

      SC 13G/A - ALTRIA GROUP, INC. (0000764180) (Subject)

      2/9/23 10:54:46 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Altria Group Inc.

      10-Q - ALTRIA GROUP, INC. (0000764180) (Filer)

      4/29/25 7:26:00 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ALTRIA GROUP, INC. (0000764180) (Filer)

      4/29/25 7:03:23 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEFA14A filed by Altria Group Inc.

      DEFA14A - ALTRIA GROUP, INC. (0000764180) (Filer)

      4/3/25 9:03:17 AM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care

    $MO
    Leadership Updates

    Live Leadership Updates

    See more
    • Altria Group, Inc. Announces Retirement of Director Jacinto J. Hernandez From Board of Directors

      Jacinto J. Hernandez, a director of Altria Group, Inc. ("Altria"), retired from service on our Board of Directors effective February 23, 2024. Mr. Hernandez will continue to serve Altria as a strategic advisor under a 5-year advisory services agreement. "We thank Jacinto for his service on our Board," said Kathryn McQuade, Altria's independent Board Chair. "Our Board benefited from his industry experience and financial expertise." "I joined Altria's Board because I am inspired by Altria's Vision to responsibly lead the transition of adult smokers to a smoke-free future," said Mr. Hernandez. "I am pleased that this agreement will allow me to focus my attention on helping Altria pursue it

      2/26/24 4:30:00 PM ET
      $ARIS
      $MO
      $PXD
      Oilfield Services/Equipment
      Energy
      Medicinal Chemicals and Botanical Products
      Health Care
    • Seasoned Financial Expert Max Yzaguirre Named Strategic Advisor of FireFly Automatix, Leader in AV and EV-Driven Professional Turfgrass Mowing Technology

      -Yzaguirre joins a list of seasoned professionals on FireFly's team with specific expertise in initiating and growing businesses in evolving market conditions- FireFly Automatix, Inc., the de facto industry leader in AV and EV professional turfgrass mowing technology, today announced the appointment of financial and leadership expert M. Max Yzaguirre as a strategic advisor to CEO Andrew Limpert and the board of directors. Yzaguirre's appointment follows the recent additions of former WPP Group CFO Paul Richardson and capital markets professional Liz Hocker to FireFly's board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202401

      1/23/24 9:00:00 AM ET
      $ARIS
      $LBC
      $MO
      Oilfield Services/Equipment
      Energy
      Major Banks
      Finance
    • Altria Group, Inc. Announces Retirement of Director Nabil Y. Sakkab From Board of Directors

      Nabil Y. Sakkab, a director of Altria Group, Inc. ("Altria") since 2008, will retire from service on our Board of Directors following the completion of his current term. Consequently, Mr. Sakkab will not stand for re-election to the Board of Directors at Altria's 2024 Annual Meeting of Shareholders, which Altria anticipates holding on May 16, 2024. "Nabil's contributions have significantly benefited Altria over the past 15 years," said Kathryn McQuade, Altria's independent Chair of the Board. "We thank him for his long and distinguished service and wish him the very best upon his retirement." Dr. Sakkab is Chair of the Innovation Committee and is a member of the Executive, Finance, and

      10/25/23 4:30:00 PM ET
      $MO
      Medicinal Chemicals and Botanical Products
      Health Care